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ABSTRACT: Introduction: Our goal was to determine whether
in vivo administration of the proteasome inhibitor MG132 can
prevent muscle atrophy caused by hindlimb unloading (HU).
Methods: Twenty-seven NMRI mice were assigned to a weight-
bearing control, a 6-day HU, or a HUþMG132 (1 mg/kg/48 h)
treatment group. Results: Gastrocnemius wasting was signifi-
cantly less in HUþMG132 mice (6.7 6 2.0%) compared with
HU animals (12.6 6 1.1%, P ¼ 0.011). HU was also associ-
ated with an increased expression of MuRF-1 (P ¼ 0.006),
MAFbx (P ¼ 0.001), and USP28 (P ¼ 0.027) mRNA, whereas
Nedd4, E3a, USP19, and UBP45 mRNA did not change signifi-
cantly. Increases in MuRF-1, MAFbx, and USP28 mRNA were
largely repressed after MG132 administration. b5 proteasome
activity tended to increase in HU (þ16.7 6 6.1%, P ¼ 0.086).
Neither b1 and b2 proteasome activities nor ubiquitin-conju-
gated proteins were changed by HU. Conclusions: Our results
indicate that in vivo administration of MG132 partially prevents
muscle atrophy associated with disuse and highlight an unex-
pected regulation of MG132 proteasome inhibitor on ubiquitin-
ligases.
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Muscle unloading is characterized by a prolonged
period of inactivity through which muscle contract-
ile activity and tension are markedly decreased.
Settings of muscle disuse, such as bed rest, trauma,
or a microgravity environment, result in rapid skel-
etal muscle atrophy due to an imbalance between
protein synthesis and degradation. The functional
consequence of muscle atrophy is a general muscle
weakness that can impair daily motion activities
and, in severe cases, have survival implications.
Therefore, a number of studies dealing with strat-
egies to prevent skeletal muscle atrophy due to
inactivity have been undertaken in recent years.
Among them, hindlimb-unloading (HU) experi-
ments have shown that the negative protein bal-
ance is at least due partly to enhanced proteoly-
sis.1,2 Three major proteolytic pathways have been
described in the skeletal muscle cell: the Ca2þ-de-
pendent pathway; the lysosomal pathway; and the
ubiquitin–proteasome pathway (UPP). There is evi-
dence that the latter is responsible for the degra-
dation of the bulk of the proteins and that this
pathway is activated during HU.1,3,4 Therefore, the
use of therapeutic agents that repress the increase
in UPP activity with unloading may be of interest.
Briefly, the UPP works in two steps. The first
step is characterized by the covalent linkage of a
polyubiquitin chain to the protein target. This link-
age is allowed by the sequential action of three
enzymes: E1 or ubiquitin-activating enzymes; E2 or
ubiquitin-carrying enzymes; and E3, also called
ubiquitin-ligases. There are several hundred E3s,
and they ensure the specificity of the UPP by tar-
geting specific proteins. Among them, muscle
RING finger-1 (MuRF-1) and atrogin-1/muscle at-
rophy F-box (MAFbx), two muscle-specific ligases,
are known to be increased in numerous models of
atrophy.5 Neural precursor cell-expressed develop-
mentally downregulated 4 (Nedd4) and E3a are
other ligases that have been shown to increase in
HU and a unilateral hindlimb immobilization
model of atrophy, respectively.6,7 The second step
of UPP implies degradation of the ubiquitinated
protein by the 26S proteasome. The central part of
the 26S proteasome is the catalytic core—called
20S—inside which the proteolytic sites are local-
ized. Three main catalytic activities have been
described: caspase-like, trypsin-like, and chymotryp-
sin-like activities, which are associated with the b1,
b2, and b5 subunits, respectively.8 More recently,
attention has been paid to another enzyme family
implicated in the UPP: de-ubiquitinating enzymes
(DUBs). Although their role in skeletal muscle at-
rophy is not yet clear, some DUBs have been
reported to increase in atrophy models.6,9
Proteasome inhibitors are among the drugs
that target the UPP.8 They can be divided into sev-
eral classes. In research, the most widely used class
of inhibitors are peptide aldehydes,8 from which
the most potent inhibitor is MG132. Two studies
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have shown that, in rats submitted to denervation
or cecal ligation and puncture (CLP), ex vivo
MG132 incubation of muscles repressed the accel-
erated proteolysis by >50%.10,11 In other in vivo
studies, local injection of MG132 in the gastrocne-
mius muscle of mdx mice—the murine model for
Duchenne muscular dystrophy—rescued muscle
structure,12 and intraperitoneal administration of
MG132 at 3 hours after CLP surgery prolonged
mouse survival.13 More recently, Supinski et al.
reported that MG132 was able to rescue endo-
toxin-induced proteolysis in the diaphragm muscle
of rats.14 Until now, few studies have been done
on the effects of proteasome inhibitor administra-
tion in unloading atrophy models15,16 and, to the
best of our knowledge, no study has been done
with HU. Therefore, the purpose of our study was
to evaluate the potential beneficial effects of
MG132 administration in vivo in the HU atrophy
model and to assess the signaling pathways
implicated.
METHODS
Animal Care. Twenty-seven male NMRI mice (11–
14 weeks old) were obtained from the animal
facilities of the Universite´ Catholique de Louvain.
Animals were housed at 22C on a 12-h dark–light
cycle with ad libitum access to food and water. All
procedures were approved by the local committee
for ethical practices in animal experiments, and
the housing conditions were as specified by the
Belgian Law of November 14, 1993, on the protec-
tion of laboratory animals (Agreement No. LA
1220548). One week after arrival, mice were placed
individually in a large cage and left for 2 days of
acclimation during which food and water were ac-
cessible on the ground only. Water was kept in a
small dish and replenished every day.
Hindlimb Suspension. Mice were randomly assigned
to either a control group (CTRL, n ¼ 9), hindlimb
unloaded group (HU, n ¼ 9), or hindlimb
unloaded plus MG132 treatment group (HUþ
MG132, n ¼ 9). On the first day of the experiment
the mice were weighed. They were then injected
with vehicle (CTRL and HU) or MG132
(HUþMG132). HU and HUþMG132 animals were
suspended. A piece of orthopedic tape was wrapped
around the tail in order to fix an unfolded paper
clip (8-shaped). The paper clip was attached to a
swivel, which allowed 360 of motion on the fore-
limbs. The swivel was fastened to the top of the
cage by nylon rope. Care was taken so that mice
were not able to use their hindlimbs on any side of
the cage, and they could not hang on the grid. Sus-
pension duration was 6 days.
MG132 Administration. HUþMG132 animals were
injected intraperitoneally every other day with
MG132 solution (1 mg/kg/48 h; Merck, Darm-
stadt, Germany). CTRL and HU groups were
injected with vehicle (2.1% dimethylsulfoxide in sa-
line solution).
Anesthesia. At the end of the suspension period,
the mice were anesthetized with a mixture of keta-
mine (200 mg/kg) and xylazine (20 mg/kg) while
they were still suspended. Animals were detached
and weighed. Right and left gastrocnemius muscles
were excised, weighed, and frozen in liquid nitro-
gen. After dissection, mice were terminally anesthe-
tized with an additional dose of ketamine–xylazine.
Muscles were kept at 80C before further analysis.
Time-Course of 20S Proteasome Inhibition by
MG132. Twenty-four male NMRI mice (12 weeks
old) were obtained and housed as described previ-
ously. They were injected intraperitoneally with 1
mg/kg MG132 (n ¼ 21) or vehicle (CTRL, n ¼ 3).
MG132-treated animals were killed after 30 min and
1, 2, 4, 8, 24, and 48 h (n ¼ 3 at each time-point).
Animals from the CTRL group were killed 1.5 h af-
ter vehicle injection. Gastrocnemius muscles were
excised, frozen in liquid nitrogen, and kept at
80C before further analysis. Proteasome activity
assay was done using the technique as described in
what follows.
Cell Culture. C2C12 cells were purchased from the
ATCC (Manassas, Virginia) and incubated at 37C
in a humidified atmosphere of 5% CO2. Myoblasts
were grown in Dulbecco modified Eagle medium
(DMEM) containing 10% fetal bovine serum
(FBS), 100 lM non-essential amino acids, 200 U/
ml penicillin, 200 lg/ml streptomycin, and 4.5 g/
L glucose, until 70% confluence, and then differ-
entiated for 120 h in a medium in which FBS was
replaced by 1% horse serum. MG132 or vehicle
was added to culture medium at a final concentra-
tion of 10 lM for 20 h. Cells were harvested using
the method described by Deldicque et al.17
Protein Extraction. Whole muscles were crushed in
a mortar in liquid nitrogen and homogenized in
ice-cold buffer containing 50 mM Tris-HCl (pH
8.0), 1 mM ethylene-glycol tetraacetic acid
(EGTA), 1 mM ethylene-diamine tetraacetic acid
(EDTA), a protease inhibitor cocktail (Roche
Applied Science, Vilvoorde, Belgium), and 10%
glycerol. The cytosolic fraction was obtained from
the centrifugation of homogenates twice at 1500g
for 10 min and once at 10,000g for 15 min, at 4C.
Supernatants were conserved at 80C. Myofibril-
lar fractions were extracted from the pellet of the
first centrifugation. Pellets were washed three
times in ice-cold buffer plus 1% Triton X-100,
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resuspended in a buffer containing 50 mM Tris-
HCl (pH 7.5), 8 M urea, and a protease inhibitor
cocktail, and stored at 80C. Protein content of
each fraction was determined in duplicate using a
DC protein assay kit (Bio-Rad, Nazareth Eke, Bel-
gium) with bovine serum albumin as a standard.
Sodium Dodecylsulfate–Polyacrylamide Gel Electro-
phoresis and Immunoblotting. Twenty-five to 40 lg
of proteins were combined with Laemmli sample
buffer. Cytosolic fractions were separated by so-
dium dodecylsulfate–polyacrylamide gel electro-
phoresis (SDS-PAGE) for 1 h at a constant inten-
sity of 40 mA. Myofibrillar fractions were run
overnight at 40 V using 4–15% gradient gels from
Bio-Rad. Proteins were transferred on polyvinyli-
dene fluoride (PVDF) membranes at 80 V for 2–4
h. Membranes were blocked 1 h in Tris-buffered
saline plus 0.1% Tween 20 (TBST) and 5% nonfat
dry milk, then incubated overnight at 4C with one
of the following primary antibodies: phospho-
Akt(Ser473), phospho-Akt(Thr308), phospho-Fox-
O1(Thr24) / FoxO3a(Thr32), IjBa, and ubiquitin
(all from Cell Signaling Technology, Leiden, The
Netherlands); and proteasome 20S a þ b and glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH)
(both from Abcam, Cambridge, UK). Membranes
were washed three times with TBST and incubated
for 1 h at room temperature with a secondary anti-
body conjugated to horseradish peroxidase. Three
washings were made again before detection by
chemiluminescence (Amersham ECL-Plus Western
Blotting Kit; GE Healthcare, Diegem, Belgium).
Films were scanned on an ImageScanner using
LabScan software, and bands were quantified with
image analysis software (Image Master 1D; Amer-
sham–GE Healthcare). GAPDH was used to ensure
equal loading for the cytosolic fraction. Ensuring
proper loading of myofibrillar proteins was done
by staining membranes with Coomassie blue.
20S Proteasome Activity Assay. b1, b2, and b5 pro-
teasomal activities were assessed on a 96-well black
plate (Greiner Bio One; Wemmel, Belgium) by the
release of 7-amino-4-methylcoumarin (AMC) using
specific substrates from Merck for each type of ac-
tivity [Z–Leu–Leu–Glu–aminomethylcoumarin (Z-
LLG-AMC), Z–Ala–Arg–Arg–aminomethylcoumarin
(Z-ARR-AMC), and Suc–Leu–Leu–Val–Tyr–amino-
methylcoumarin (Suc-LLVY-AMC), respectively].
Ten micrograms of cytosolic proteins, 200 ll of
buffer [Tris-HCl 50 mM (pH 8), MgCl2 5 mM, and
dithiothreitol (DTT) 1 mM], and 100 lM fluores-
cent-specific substrate were put in each well. Each
sample was realized in quadruplicate for each activ-
ity, one of them being incubated with 50 lM
MG132 to assess specificity of the activity. Fluores-
cence intensity was measured at 37C during 30
min on a fluorometer (Fluoroskan Ascent FL;
Thermo Scientific, Zellik, Belgium). One measure-
ment was done every 2 min at excitation and emis-
sion wavelengths of 370 nm and 460 nm, respec-
tively. Activities were calculated as the slope of the
accumulation of fluorescence as a function of time
and were expressed relative to an internal control
sample that had been put on each plate.
RNA Extraction and Quantitative Real-Time PCR. Tis-
sue samples were homogenized with a pestle in 1
ml of Trizol reagent (Invitrogen, Vilvoorde, Bel-
gium), and RNA was isolated according to the
manufacturer’s instructions. RNA quality and
quantity were assessed by 1.5% agarose gel electro-
phoresis and Nanodrop spectrophotometry.
Reverse transcription (RT) was performed on
MyIQ2 thermocycler (Bio-Rad). Firstly, 1.5 lg of
RNA was added with 1 ll of oligo-dT12–18 primers,
1 ll DNTPs, and RNase-free water for a final vol-
ume of 12 ll that was run for 5 min at 65C. For
the second step (2 min, 42C), 4 ll of 5 first-
strand buffer, 2 ll of 0.1 M DTT, and 1 ll RNase-
OUT were added to the samples. Finally, 1 ll of
Superscript II was added, and the final RT product
was obtained after a run of 50 min at 42C and 15
min at 72C. Primers used for quantitative PCR are
reported in Table 1. Cyclophilin (Cphn) was used
as a reference gene. Experiments were performed
on a MyIQ2 thermocycler, under the following
conditions: 3 min at 95C, followed by 35 cycles of
30 s at 95C, 30 s at 60C, and 30 s at 72C. Genes
were analyzed in triplicate for each sample in a 25-
ll reaction volume containing 12.5 ll of IQ Sybr-
Green SuperMix (Bio-Rad), 0.5 ll of each primer
(100 nM final), and 12 ll of cDNA with the appro-
priate dilution. Melting curves were systematically
assessed for quality control. Data were normalized
to Cphn, which remained unchanged.
Statistical Analysis. Values are presented as mean
6 SEM. A one-way analysis of variance (ANOVA),
followed by a Student–Newman–Keuls post hoc
test, was used for statistical analysis. Statistical sig-
nificance was set at P < 0.05.
RESULTS
Body and Muscle Weight. After 6 days of suspen-
sion, body weight was diminished by 4.9 6 1.5% in
the HU group (P ¼ 0.028), which was not reversed
by MG132 treatment (Table 2). The gastrocnemius
muscle weight was 12.6 6 1.1% lower in HU com-
pared with CTRL animals (P < 0.001). After
MG132 administration, gastrocnemius muscle was
significantly heavier than in the HU group (P ¼
0.011) as muscle weight was 6.7 6 2.0% lower in
HUþMG132 compared with CTRL (P ¼ 0.005).
The ratio of gastrocnemius/body weight of the
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HU animals was 11.0 6 1.2% lower than that of
the CTRL group (P < 0.001). In MG132-treated
animals, the ratio was only 5.7 6 1.6% lower than
that of the CTRL group (P ¼ 0.009), and it was
significantly greater than in the HU group (P ¼
0.012) (Table 2).
Components of the Ubiquitin–Proteasome Pathway. Mu
RF-1 and MAFbx mRNA expression levels were
higher in HU animals than in CTRL animals by 2.7
6 0.5-fold (P ¼ 0.006) and 2.2 6 0.2-fold (P ¼
0.001), respectively (Fig. 1A). Nedd4 mRNA was
increased by 1.8 6 0.3-fold, but this change did not
reach statistical significance (P ¼ 0.144). The level
of E3a mRNA was not different in the three condi-
tions (Fig. 1A). When MG132 was administered to
HU animals, the increase in MuRF-1 mRNA was
almost completely blunted (HUþMG132 vs. HU: P
¼ 0.005) and was reduced by about two-thirds for
MAFbx (HUþMG132 vs. HU: P ¼ 0.010). Nedd4
mRNA expression was not affected significantly by
MG132. The amount of ubiquitin-conjugated pro-
teins (UbCPs) was unaffected either by HU or by
MG132 in vivo even though C2C12 cell incubation
with 10 lM MG132 for 20 h increased UbCPs by
12.6 6 2.5-fold (P ¼ 0.010, Fig. 1B). USP28 mRNA
was 1.7 6 0.2-fold higher (P ¼ 0.027) in HU ani-
mals. The increase was reversed by 90.9% with
MG132 (HUþMG132 vs. HU: P ¼ 0.018) (Fig. 1C).
Two other de-ubiquitinating enzymes (USP19 and
UBP45) were unaffected, regardless of the condi-
tion studied. HU tended to increase proteasome b5
activity (þ16.7 6 6.1%; P ¼ 0.086), whereas b1 and
b2 activities were unchanged. MG132 administration
did not change proteasome activity in vivo, whereas
incubation of C2C12 cells with 10 lM MG132 for
20 h reduced b5 activity by 94.1% (P < 0.001; Fig.
1D). The protein level of proteasome 20S a þ b
subunits remained unaffected by any condition
(Fig. 1E).
Regulation of Ligase mRNA Expression. Because of
the unexpected results for ligases, we measured
markers of activation of the main transcription fac-
tors currently known to regulate mRNA ligase
expression: nuclear factor–kappa light-chain
enhancer of activated B cells (NF-jB) and fork-
head box O (FoxO).18 Under basal conditions, NF-
jB family members are kept in the cytosol by the
NF-jB inhibitor protein nuclear factor of kappa
light polypeptide gene enhancer in B cells inhibi-
tor alpha (IjBa). Under atrophy signal, IjBa
becomes phosphorylated, which marks it for ubiq-
uitination and subsequent proteasomal degrada-
tion. Therefore, MG132 could possibly regulate
ligase mRNA expression by preventing IjBa degra-
dation. Under the present conditions, cytosolic
IjBa protein expression remained unaffected
Table 1. Sequences of primers (50–30).
Gene Forward Reverse
Cphn CGTCTCCTTCGAGCTGTTTG CCACCCTGGCACATGAATC
E3a ACTGGTCCGGCTAGAGATGAT CCTCCACAACCAACTGAAAAA
MAFbx CCATCAGGAGAAGTGGATCTATGTT GCTTCCCCCAAAGTGCAGTA
MuRF-1 ACGACATCTTCCAGGCTGCGAATCC TCTCGTCTTCGTGTTCCTTGC
Nedd4 TCGGAGGACGAGGTATGGG GGTACGGATCAGCAGTGAACA
USP19 CAGGTTGAGGCTGAGGAGA GACTCTGGTTCCTCCACCAA
USP28 CCGAACTCTTCCTCACAGGAT CCTGAGCCACCTTCATGATAC
UBP45 CATTGCTGTAGGTCTAACGTGC CCAAACATCAGCAGGCAGTA
Cphn, cyclophilin A; MAFbx, muscle atrophy F-box; MuRF-1, muscle RING finger-1; Nedd4, neural precursor cell-expressed developmentally
downregulated 4; USP19, ubiquitin-specific peptidase 19; USP28, ubiquitin-specific peptidase 28; UBP45, ubiquitin-binding protease 45.
Table 2. Body and gastrocnemius weight.
Parameter CTRL (n ¼ 9) HU (n ¼ 9) HUþMG132 (n ¼ 9)
Initial body weight (g) 41.4 6 0.7 40.9 6 1.0 41.1 6 0.8
Final body weight (g) 41.2 6 1.0 38.9 6 1.2 39.0 6 0.8
Body weight change (%) 0.62 6 1.23 4.94 6 1.50* 4.97 6 1.17
Gastrocnemius weight (mg) 193.8 6 2.8 169.3 6 2.1‡ 180.8 6 4.0†,§
Gastrocnemius weight/body
weight ratio (mg/g)
4.67 6 0.07 4.15 6 0.06‡ 4.40 6 0.08†,§
Weight of gastrocnemius was measured in left and right muscles. Values expressed as mean 6 SEM. CTRL, controls; HU, hindlimb unloading.
*P < 0.05.
†P < 0.01.
‡P < 0.001 vs. CTRL.
§P < 0.05 vs. HU.
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either by HU or by HUþMG132 treatment (Fig.
2A). Another pathway known to regulate muscle
ligase mRNA expression is the Akt/FoxOs pathway.
Disuse signaling results in inactivation of Akt and
thereby dephosphorylation of FoxOs, which trans-
locate to the nucleus and activate transcription of
target genes. We measured phosphorylation states
of Akt, FoxO1, and FoxO3a, but they remained
unaffected under the present conditions (Fig. 2B).
Time-Course of 20S Proteasome Inhibition by
MG132. The pharmacodynamic profile of MG132
was evaluated by measuring b5 activity in gastro-
cnemius of NMRI mice injected intraperitoneally
with 1 mg/kg MG132. The time-course of 20S pro-
teasome inhibition by MG132 is shown in Figure 3.
Proteasome b5 activity of gastrocnemius decreased
between 2 and 8 h after injection to reach 12% in-
hibition compared with control muscles from
FIGURE 1. Effects of 6 days of HU and MG132 treatment on expression of gastrocnemius mRNA ligases (A), ubiquitin-conjugated
protein (UbCP) expression; a positive control obtained in myogenic C2C12 cells after 10 lM MG132 administration is provided (B),
DUB mRNA expression (C), proteasome activity; a positive control obtained in myogenic C2C12 cells after 10 lM MG132 administra-
tion is provided (D) and proteasome 20S a þ b protein expression (E). Representative Western blots are shown below their respective
bars. Values are expressed as mean 6 SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. CTRL; †P < 0.05 vs. HU.
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vehicle-injected mice. Then, proteasome b5 activity
re-increased progressively over time, but it was still
slightly lower 48 h after injection (8%). This was
in accordance with the results obtained in the
HUþMG132-treated group.
DISCUSSION
The gastrocnemius muscle atrophy that we
observed after a 6-day HU period in mice (12.6 6
1.1%) was similar to that observed in previous
studies carried out on the same model.5,19 We
showed that in vivo administration of the protea-
some inhibitor MG132 was effective for rescuing
muscle mass in a disuse atrophy model. The dose
of drug administered was 1 mg/kg, which is similar
to the amount used in other in vivo animal stud-
ies.13,14 Bortezomib, another proteasome inhibitor,
has been administered twice per week in patients
with refractory hematologic malignancies.20 To
investigate a clinically relevant administration
schedule, MG132 was administrated every 2 days in
this study. This regimen reduced gastrocnemius at-
rophy by about 50%, but it did not reverse body
weight loss, suggesting a muscle-specific action of
MG132. Holecek et al.21 reported that MG132
administered in vivo inhibited b5 activity of protea-
some in skeletal muscle, but not in other organs.
In our study, we showed that MG132 affects two
other components of the ubiquitin–proteasome
pathway, namely the muscle-specific ubiquitin-
ligases MuRF-1 and MAFbx (Fig. 1A) and USP28
de-ubiquitinase (Fig. 1C).
Muscle-specific ligase MuRF-1 and MAFbx
mRNAs have been reported to be upregulated in
various muscle atrophy models and seem to be
part of a common program activated in all atrophy
models.5 This is not the case for Nedd4, which has
been shown to increase during atrophy due to
reduced muscle tension but not in cachexia-related
atrophy.22 In accordance with the literature,5 we
found that HU induced a clear increase in mRNA
expression of MuRF-1 and MAFbx. The increase in
Nedd4 mRNA expression following HU did not
reach statistical threshold under our conditions.
Even as E3a mRNA expression was reported to
increase in unilateral hindlimb immobilization,6 it
did not change in our conditions.
De-ubiquitinase function in skeletal muscle at-
rophy is much less clear than that for ubiquitin-
ligases. It seems that DUBs can behave as either
pro- or anti-atrophic components of the UPP path-
way. They can spare proteasome substrates from
degradation, yet they can recycle ubiquitin after
substrate degradation or process the translational
product of the polyubiquitin gene to its mature
form.23 We observed a significant increase in
FIGURE 3. Time-course of proteasome b5 activity in gastrocne-
mius muscle of NMRI mice after an intraperitoneal injection of 1
mg/kg MG132 (filled circles) or after injection of the vehicle
(open triangle). Values are expressed as mean 6 SEM (n ¼ 3
at each time-point).
FIGURE 2. Effects of 6 days of HU and MG132 treatment on markers of pathways known to regulate expression of mRNA muscle ligases.
Levels of IjBa (A) and phosphorylated forms of Akt, FoxO1, and FoxO3a (B) are normalized to levels of GAPDH and compared with their
expression in control muscles. Representative Western blots are shown below their respective bars. Values are expressed as mean 6 SEM.
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USP28 mRNA under atrophy due to HU. The
same trend was observed recently by Baptista et al.
in a model of unilateral hindlimb immobilization.6
The fact that an increase in USP28 was repressed
by MG132 administration suggests that ligases like
MuRF-1 and MAFbx share a common pathway of
regulation with de-ubiquitinases like USP28. Even
as USP19 and UBP45 mRNA were reported to
increase in various atrophy models,6,9 they did not
change in our HU model.
The increase in MuRF-1, MAFbx, and USP28
mRNA was largely repressed after MG132 adminis-
tration. Two major pathways have been implicated
in the regulation of muscle-specific ligase mRNA
expression during disuse atrophy: the NF-jB path-
way and the IGF-1/PI3K/Akt pathway.24 Transloca-
tion of NF-jB factors into the nucleus is permitted
when proteasomal IjBa degradation occurs. There-
fore, MG132 can prevent NF-jB activation by in-
hibiting IjBa degradation. Under our conditions,
IjBa was unchanged after 6 days of HU. Neverthe-
less, we cannot rule out implications of this path-
way in the repression of ligase mRNA, because
IjBa may have been degraded at the onset of the
unloading period and returned to basal levels after
6 days, whereas MuRF-1 and MAFbx mRNAs
remained elevated.
As MG132 has been shown to increase skeletal
muscle protein synthesis,21 it could also prevent an
increase in MuRF-1 and MAFbx expression by act-
ing through the IGF-1/PI3K/Akt pathway, thereby
increasing FoxO1 and FoxO3a phosphorylation
states and keeping them in the cytosol. This hy-
pothesis was not corroborated by our results, which
showed no change in Akt or in FoxO1 and FoxO3a
phosphorylation states.
The fact that HU did not increase UbCP level
was unexpected, as several studies reported an
increase with similar unloading time periods.15,25
The explanation for this discrepancy is not
obvious. Western blotting allows determination of
the amount of ubiquitinated proteins but does not
reflect a change in UbCP turnover. As a conse-
quence, the ubiquitination–de-ubiquitination–deg-
radation process might be increased even when
the amount of UbCP remains stable. The fact that
MuRF-1, MAFbx, and USP28 mRNA as well as b5
activity were all increased in response to HU sup-
ports this hypothesis.
In basal conditions b5 activity accounted for
79% of the total proteasome activity, whereas b1
and b2 accounted for 17% and 4%, respectively.
These findings are in accordance with the protea-
some relative catalytic activities reported previously
in rat gastrocnemius.26 In our experiment, absolute
values for CTRL activities of b1, b2, and b5 subu-
nits averaged 49.4 6 2.3, 11.2 6 0.8, and 229.5 6
13.6 pmol AMC/min/mg protein, respectively. Pro-
teasome b5 activity tended to increase with HU,
whereas b1 and b2 activities did not change signifi-
cantly. This is comparable to both absolute CTRL
values and changes in catalytic activities observed
in rat soleus muscle after 5-day HU.25
Protein extraction was performed in the pres-
ence of a protease inhibitor cocktail. One might
expect that the use of protease inhibitors would
lower proteasome activity. We tested the impact of
the use of the protease inhibitor cocktail (Com-
plete Mini; Roche Applied Science) during protein
extraction on a proteasome b5 activity assay. Pro-
teasome b5 activity was 39% lower when the pro-
tein extraction procedure was conducted in the ab-
sence of protease inhibitors (n ¼ 3, P ¼ 0.002).
The protease inhibitor cocktail that we used is
known to inhibit serine, cysteine, and aspartate
proteases and metalloproteases, whereas the cata-
lytic sites on the b1, b2, and b5 subunits of protea-
some are threonine proteases.27,28 Therefore, it is
not surprising that b5 activity was not diminished.
Instead, the inhibitor cocktail may prevent the deg-
radation of proteasome subunits by serine, cyste-
ine, and aspartate proteases and metalloproteases
in the cells, thus leading to greater activity in vitro.
We did not observe any change in proteasome
20S a þ b protein expression, suggesting that the
increase in b5 activity with HU was due to a regula-
tion of 20S affinity for its substrates or an
increased intrinsic peptidase activity. This impli-
cates the association of proteasome activator PA28
(i.e., 11S) or PA200 with the 20S proteasome.29–31
In atrophy models, increased mRNA levels have
been observed for both a and b PA28 subunits in
response to unloading.32 PA200 has been discov-
ered more recently,33 and its physiological func-
tion during disuse atrophy has not been estab-
lished. Attachment of 19S to each extremity of 20S
forms proteasome 26S, which is responsible for
ubiquitin-mediated degradation. This process con-
sumes adenosine triphosphate (ATP). As our in
vitro assays were run in the absence of ATP, it is
unlikely that the increase in b5 activity was due to
19S regulation. Posttranslational modifications,
especially changes in phosphorylation states of 20S
subunits, are other mechanisms that can influence
20S specific activity. Proteasome intrinsic activity
can be increased by PKA phosphorylation of sev-
eral 20S subunits.34
Although MG132 (1 mg/kg) injected every 48
h could diminish HU-induced atrophy, no signifi-
cant proteasome inhibition was observed in
HUþMG132 with in vitro assays when compared
with HU. MG132 is known to affect mainly b5 ac-
tivity,35 and we were able to measure a strong inhi-
bition of this activity in C2C12-cultured cells
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incubated for 20 h with 10 lM MG132, thus sug-
gesting that competitive inhibition of 20S by
MG132 was maintained during the extraction pro-
cedure. It has been suggested that MG132 was less
effective for inhibiting proteasome activity in skele-
tal muscle incubated in vitro than in cultured myo-
genic cells, likely because of a lower sensitivity of
the differentiated muscle cell.10 To the best of our
knowledge, the pharmacokinetics of MG132 have
not been studied systematically. The pharmacoki-
netics of other proteasome inhibitors have been
determined, and blood concentrations of the
drugs were measured by liquid chromatography
with tandem mass spectrometry detection.36,37 The
drugs are rapidly removed from the vascular com-
partment. Alternative methods using proteasome
in vitro activity measurement have been used to
determine drug pharmacodynamic profiles.38
Therefore, we analyzed the time-course of 20S pro-
teasome inhibition by MG132 by measuring b5 ac-
tivity in the gastrocnemius of NMRI mice injected
intraperitoneally with 1 mg/kg MG132, which was
the dose used in our study. The results show that
the b5 proteasome was inhibited by 12% at 8 h af-
ter injection, and thereafter the activity was pro-
gressively restored. Due to the format of the data
matrix (7 time-points and 3 animals for each time-
point), application of a kinetic model was inappro-
priate, and our statistical analysis (ANOVA) did
not reach the significance threshold. Although the
main goal of our study was not to describe the
pharmacodynamics of MG132, these data provide
relevant information about the MG132-induced in-
hibition of proteasome b5 activity over time in skel-
etal muscle. Clearly, further studies are needed to
describe the MG132 pharmacokinetics.
A limitation of this study is the absence of his-
tological and functional analyses of the muscle.
Having demonstrated that a proteasome inhibitor
like MG132 is effective for protecting muscle mass
after HU, further studies are required to shed light
on structure, functional capabilities, and metabolic
consequences of muscle mass preservation. This
study included an early time-point of 6 days, and
the potential beneficial effects of MG132 for lon-
ger periods as well as long-term tolerability still
have to be assessed. Noticeably, HUþMG132 ani-
mals did not show any gross side effects when
MG132 was given every other day. Although our
results suggest an unexpected regulation of mus-
cle-specific ligases as well as USP28 by MG132,
other protein degradation pathways may be
affected. Indeed, MG132 has been reported to in-
hibit cathepsins and calpains, but at a tenfold
higher concentration.8
In conclusion, our results show that MG132
administration in vivo can repress muscle atrophy
due to reduced muscle tension. Unexpectedly, this
protective effect seems to involve regulation of
expression of muscle ubiquitin-ligases. This obser-
vation reinforces the hypothesis that regulation of
muscle ligases is critical for prevention of skeletal
muscle atrophy. The signaling pathways responsi-
ble for this regulation still need to be fully
elucidated.
The authors thank Hermann Zbinden and Willy Marteau for
their technical assistance. This study was supported by the
Fonds de la Recherche Scientifique Me´dicale (FRSM
3.4574.03) (Belgium) and by the UCLouvain (FSR). G.L.A. was
supported by the Association Belge contre les Maladies Neuro-
Musculaires.
REFERENCES
1. Lecker SH, Solomon V, Mitch WE, Goldberg AL. Muscle protein
breakdown and the critical role of the ubiquitin–proteasome
pathway in normal and disease states. J Nutr 1999;129(suppl):227S–
237S.
2. Yimlamai T, Dodd SL, Borst SE, Park S. Clenbuterol induces muscle-
specific attenuation of atrophy through effects on the ubiquitin–pro-
teasome pathway. J Appl Physiol 2005;99:71–80.
3. Reid MB. Response of the ubiquitin–proteasome pathway to changes
in muscle activity. Am J Physiol Regul Integr Comp Physiol 2005;288:
R1423–R1431.
4. Taillandier D, Combaret L, Pouch MN, Samuels SE, Bechet D, Attaix
D. The role of ubiquitin–proteasome-dependent proteolysis in the
remodelling of skeletal muscle. Proc Nutr Soc 2004;63:357–361.
5. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA,
et al. Identification of ubiquitin ligases required for skeletal muscle
atrophy. Science 2001;294:1704–1708.
6. Baptista IL, Leal ML, Artioli GG, Aoki MS, Fiamoncini J, Turri AO,
et al. Leucine attenuates skeletal muscle wasting via inhibition of
ubiquitin ligases. Muscle Nerve 2010;41:800–808.
7. Dupont-Versteegden EE, Fluckey JD, Knox M, Gaddy D, Peterson
CA. Effect of flywheel-based resistance exercise on processes contrib-
uting to muscle atrophy during unloading in adult rats. J Appl Phys-
iol 2006;101:202–212.
8. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools
to drug candidates. Chem Biol 2001;8:739–758.
9. Combaret L, Adegoke OA, Bedard N, Baracos V, Attaix D, Wing SS.
USP19 is a ubiquitin-specific protease regulated in rat skeletal mus-
cle during catabolic states. Am J Physiol Endocrinol Metab 2005;288:
E693–E700.
10. Tawa NE Jr, Odessey R, Goldberg AL. Inhibitors of the proteasome
reduce the accelerated proteolysis in atrophying rat skeletal muscles.
J Clin Invest 1997;100:197–203.
11. Kadlcikova J, Holecek M, Safranek R, Tilser I, Kessler BM. Effects of
proteasome inhibitors MG132, ZL3VS and AdaAhx3L3VS on protein
metabolism in septic rats. Int J Exp Pathol 2004;85:365–371.
12. Bonuccelli G, Sotgia F, Schubert W, Park DS, Frank PG, Woodman
SE, et al. Proteasome inhibitor (MG-132) treatment of mdx mice res-
cues the expression and membrane localization of dystrophin and
dystrophin-associated proteins. Am J Pathol 2003;163:1663–1675.
13. Safranek R, Ishibashi N, Oka Y, Ozasa H, Shirouzu K, Holecek M.
Modulation of inflammatory response in sepsis by proteasome inhibi-
tion. Int J Exp Pathol 2006;87:369–372.
14. Supinski GS, Vanags J, Callahan LA. Effect of proteasome inhibitors
on endotoxin-induced diaphragm dysfunction. Am J Physiol Lung
Cell Mol Physiol 2009;296:L994–L1001.
15. Krawiec BJ, Frost RA, Vary TC, Jefferson LS, Lang CH. Hindlimb
casting decreases muscle mass in part by proteasome-dependent pro-
teolysis but independent of protein synthesis. Am J Physiol Endocri-
nol Metab 2005;289:E969–E980.
16. Beehler BC, Sleph PG, Benmassaoud L, Grover GJ. Reduction of
skeletal muscle atrophy by a proteasome inhibitor in a rat model of
denervation. Exp Biol Med (Maywood) 2006;231:335–341.
17. Deldicque L, Theisen D, Bertrand L, Hespel P, Hue L, Francaux M.
Creatine enhances differentiation of myogenic C2C12 cells by activat-
ing both p38 and Akt/PKB pathways. Am J Physiol Cell Physiol 2007;
293:C1263–1271.
18. Chopard A, Hillock S, Jasmin BJ. Molecular events and signalling
pathways involved in skeletal muscle disuse-induced atrophy and the
impact of countermeasures. J Cell Mol Med 2009;13:3032–3050.
19. Ferreira R, Vitorino R, Neuparth MJ, Appell HJ, Duarte JA, Amado
F. Proteolysis activation and proteome alterations in murine skeletal
MG132 and Hindlimb Unloading MUSCLE & NERVE May 2011 715
muscle submitted to 1 week of hindlimb suspension. Eur J Appl
Physiol 2009;107:553–563.
20. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS,
Stahl S, et al. Phase I trial of the proteasome inhibitor PS-341 in
patients with refractory hematologic malignancies. J Clin Oncol
2002;20:4420–4427.
21. Holecek M, Muthny T, Kovarik M, Sispera L. Proteasome inhibitor
MG-132 enhances whole-body protein turnover in rat. Biochem Bio-
phys Res Commun 2006;345:38–42.
22. Koncarevic A, Jackman RW, Kandarian SC. The ubiquitin–protein
ligase Nedd4 targets Notch1 in skeletal muscle and distinguishes the
subset of atrophies caused by reduced muscle tension. FASEB J
2007;21:427–437.
23. Wing SS. Control of ubiquitination in skeletal muscle wasting. Int J
Biochem Cell Biol 2005;37:2075–2087.
24. Zhang P, Chen X, Fan M. Signaling mechanisms involved in disuse
muscle atrophy. Med Hypotheses 2007;69:310–321.
25. Berthon P, Duguez S, Favier FB, Amirouche A, Feasson L, Vico L,
et al. Regulation of ubiquitin–proteasome system, caspase enzyme
activities, and extracellular proteinases in rat soleus muscle in
response to unloading. Pflugers Arch 2007;454:625–633.
26. Farout L, Lamare MC, Cardozo C, Harrisson M, Briand Y, Briand M.
Distribution of proteasomes and of the five proteolytic activities in
rat tissues. Arch Biochem Biophys 2000;374:207–212.
27. Glickman MH, Ciechanover A. The ubiquitin–proteasome proteolytic
pathway: destruction for the sake of construction. Physiol Rev 2002;
82:373–428.
28. Lee DH, Goldberg AL. Proteasome inhibitors: valuable new tools for
cell biologists. Trends Cell Biol 1998;8:397–403.
29. Ferrington DA, Husom AD, Thompson LV. Altered proteasome
structure, function, and oxidation in aged muscle. FASEB J 2005;19:
644–646.
30. Stohwasser R, Salzmann U, Giesebrecht J, Kloetzel PM, Holzhutter
HG. Kinetic evidences for facilitation of peptide channelling by the
proteasome activator PA28. Eur J Biochem 2000;267:6221–6230.
31. Rechsteiner M, Hill CP. Mobilizing the proteolytic machine: cell bio-
logical roles of proteasome activators and inhibitors. Trends Cell
Biol 2005;15:27–33.
32. Attaix D, Taillandier D, Combaret L, Ralliere C, Larbaud D, Aurous-
seau E, et al. Expression of subunits of the 19S complex and of the
PA28 activator in rat skeletal muscle. Mol Biol Rep 1997;24:95–98.
33. Ustrell V, Pratt G, Gorbea C, Rechsteiner M. Purification and assay
of proteasome activator PA200. Methods Enzymol 2005;398:321–329.
34. Zong C, Gomes AV, Drews O, Li X, Young GW, Berhane B, et al.
Regulation of murine cardiac 20S proteasomes: role of associating
partners. Circ Res 2006;99:372–380.
35. Myung J, Kim KB, Crews CM. The ubiquitin–proteasome pathway
and proteasome inhibitors. Med Res Rev 2001;21:245–273.
36. Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger
A, et al. Evaluation of the proteasome inhibitor MLN9708 in preclin-
ical models of human cancer. Cancer Res 2010;70:3853.
37. Attar EC, De Angelo DJ, Supko JG, D’Amato F, Zahrieh D, Sirulnik
A, et al. Phase I and pharmacokinetic study of bortezomib in combi-
nation with idarubicin and cytarabine in patients with acute myeloge-
nous leukemia. Clin Cancer Res 2008;14:1446–1454.
38. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ.
Proteasome inhibition measurements: clinical application. Clin
Chem 2000;46:673–683.
716 MG132 and Hindlimb Unloading MUSCLE & NERVE May 2011
